Male breast cancer: thirteen years experience of a single center

International Seminars in Surgical Oncology - Tập 6 - Trang 1-5 - 2009
Sami Akbulut1, Ilker Arer1, Alper Kocbiyik2, Mahmut Can Yağmurdur1, Hamdi Karakayalı1, Mehmet Haberal1
1Department of Surgery, University Hospital of Baskent, Ankara, Turkey
2Department of Pathology, University Hospital of Baskent, Ankara, Turkey

Tóm tắt

This retrospective study analysed the epidemiological, clinical, and therapeutic profiles of breast cancer in males. We report our experience at the Hospital of the University of Baskent, where 20 cases of male breast cancer were observed and treated between 1995–2008. Median age at presentation was 66,7 ± 10,9 years. Average follow-up was 63 ± 18,5 months. The main presenting symptom was a mass in 65% of cases (13 patients). Ýnvasive ductal carcinoma was the most frequent pathologic type (70% of cases). Male breast cancer patients have an incidence of prostate cancer higher than would be predicted in the general population. Cause of men have a higher rate of ER positivity the responses with hormonal agents are good.

Tài liệu tham khảo

English JC, Middleton C, Patterson JW, Slingluff CL: Cancer of the male breast. J Dermatol. 2000, 39 (12): 881-6. El Omari-Alaoui H, Lahdiri I, Nejjar I, Hadadi K, Ahyoud F, Hachi H, Alhilal M, Errihani H, Benjaafar N, Souadka A, El Gueddari BK: Male breast cancer. A report of 71 cases. Cancer/Radiother. 2002, 6 (6): 349-351. 10.1016/S1278-3218(02)00250-0. Lanitis S, Rice AJ, Vaughan A, Cathcart P, Filippakis G, Mufti RA, Hadjiminas DJ: Diagnosis and management of Male Breast Cancer. World Journal of Surgery. 2008, 32 (11): 2471-6. 10.1007/s00268-008-9713-7. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report. J Clin Oncol. 2002, 20 (15): 3317-27. 10.1200/JCO.2002.06.020. Liberman L, Bracero N, Vuolo MA, Dershaw DD, Morris EA, Abramson AF, Rosen PP: Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol. 1999, 172 (2): 331-7. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H: Male breast cancer: is the scenario changing. World J Surg Oncol. 2008, 6: 58-10.1186/1477-7819-6-58. El Hajjam M, Khaiz D, Benider A, Lakhloufi A, Abi F, Kahlain A, Bouzidi A: Cancer of the breast in men. Apropos of 50 cases. J Chir (Paris). 1995, 132 (3): 131-6. Herman K, Lobaziewicz W, Skotnicki P, Fortuna J, Kusy T, Leśniak T: Male breast cancer. Does the prognosis differ compared to female?. Neoplasm. 2000, 47 (3): 191-5. Tajima N, Tsukuma H, Oshima : Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol. 2001, 11 (1): 1-7. Lee UJ, Jones JS: Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis. 2008, Winchester DJ: Male breast carcinoma: a multiinstitutional challenge. Cancer. 1998, 83 (3): 399-400. 10.1002/(SICI)1097-0142(19980801)83:3<399::AID-CNCR3>3.0.CO;2-K. Donegan WL, Redlich PN, Lang PJ, Gall MT: Carcinoma of the breast. A multiinstitutional survey. Cancer. 1998, 83 (3): 498-509. 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R. Stranzl H, Mayer R, Quehenberger F, Prettenhofer U, Willfurth P, Stöger H, Hackl A: Adjuvant radiotherapy in male breast cancer. Radiotherapy and Oncology. 1999, 53 (1): 29-35. 10.1016/S0167-8140(99)00122-X. Vetto J, Jun SY, Padduch D, Eppich H, Shih R: Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg. 1999, 177 (5): 379-83. 10.1016/S0002-9610(99)00067-7.